Released Nov 13, 2026, before the open
10-Q filed Nov 16, 2026, 47 days after period end · 0001140361-26-043844
Announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC with additional participation from current investors.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$7.62M | -$9.01M | -$10.73M | -$10.85M |
| EPS Diluted | -$0.11 | -$0.19 | -$0.29 |
PDS Biotechnology Corp · CIK 1472091 · Engraved from SEC EDGAR
| -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
PDS Biotechnology announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC, with a contingent milestone closing triggered by FDA submission of a registrational Phase 3 protocol for PDS0301.¶1¶2
The Company reported a net loss of $7.6 million, or $0.11 per basic and diluted share, for the three months ended September 30, 2026, compared to $9.0 million, or $0.19 per share, a year earlier.¶3
Cash and cash equivalents were $15.2 million as of September 30, 2026.¶4
Research and development expenses were $2.1 million and general and administrative expenses were $3.8 million for the three months ended September 30, 2026, for total operating expenses of $5.9 million.¶5¶6¶7